Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precision BioSciences’ ARCUS genome-editing breakthroughs look exciting—until you hit the 300-page disclosure explaining clinical trial data, FDA feedback, and milestone accounting. If finding pipeline updates or cash-runway details in a biotech 10-K feels like lab work, you’re not alone.
Stock Titan decodes every DTIL annual report 10-K simplified and DTIL quarterly earnings report 10-Q filing the moment they appear on EDGAR. Our AI highlights where the company reports dose-escalation results, collaboration revenue, and new GMP manufacturing spend, turning DTIL SEC filings explained simply from wishful thinking into reality. Need material news fast? See DTIL 8-K material events explained minutes after submission, or track DTIL Form 4 insider transactions real-time—including DTIL executive stock transactions Form 4—before the market reacts.
What investors actually do with this data:
- Compare R&D burn rates quarter-over-quarter using our DTIL earnings report filing analysis
- Monitor DTIL insider trading Form 4 transactions for confidence signals ahead of trial read-outs
- Review the DTIL proxy statement executive compensation section to align incentives
The result? You spend minutes, not hours, understanding DTIL SEC documents with AI. Every filing type, every footnote, delivered in real time—so you can focus on whether ARCUS is truly a cut above the rest.
Precision BioSciences Schedule 13G/A shows that Readout-affiliated entities and Matthew Smith reported collective beneficial ownership of up to 1,119,311 shares of the issuer's common stock as of June 30, 2025, representing approximately 9.4% of the outstanding class. The filing breaks ownership across Readout Capital, Readout Capital GP, ROC Holdings SPV II, Readout Holdings GP and Matthew Smith, and discloses that ROC SPV II directly held 686,437 shares plus warrants exercisable into 220,000 shares. Readout Capital also manages a separate account holding 200,000 shares under an investment management agreement. Signatures certify the disclosures.
Schedule 13G summary: Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach report beneficial ownership of 1,075,000 common shares of Precision BioSciences, representing 9.69% of the outstanding common stock. The filing shows the reporting persons hold sole voting and sole dispositive power over these shares and report no shared voting or dispositive power. Bleichroeder LP is identified as an investment adviser and is deemed to beneficially own the shares as adviser to various clients, while those clients retain the right to dividends and sale proceeds. The filing is submitted on Schedule 13G with exhibits for an agreement among reporting persons and subsidiary information.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 reporting that director Melinda Brown purchased 1,682 common shares on June 25 2025 at a weighted-average price of $4.14–$4.15. Following the transaction, Brown’s direct beneficial ownership increased to 20,565 shares.
No other non-derivative or derivative transactions were disclosed, and there were no sales. The filing contains a standard footnote explaining the weighted-average price range. No 10b5-1 trading plan box was checked.
FAQ
What is the current stock price of Precision Biosciences (DTIL)?
What is the market cap of Precision Biosciences (DTIL)?
